160 related articles for article (PubMed ID: 37669776)
1. Metformin shows anti-neoplastic properties by inhibition of oxidative phosphorylation and glycolysis in epidermolysis bullosa-associated aggressive cutaneous squamous cell carcinoma.
Welponer T; Weber DD; Trattner L; Tockner B; Aminzadeh-Gohari S; Leb-Reichl V; Kaufmann A; Zauner R; Wimmer M; Wally V; Felder TK; Strunk D; Koller U; Bauer JW; Kofler B; Guttmann-Gruber C; Piñon Hofbauer J
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):112-123. PubMed ID: 37669776
[TBL] [Abstract][Full Text] [Related]
2. Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases.
Hwang A; Kwon A; Miller CH; Reimer-Taschenbrecker A; Paller AS
Orphanet J Rare Dis; 2024 May; 19(1):206. PubMed ID: 38769503
[TBL] [Abstract][Full Text] [Related]
3. Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis Bullosa.
Rami A; Łaczmański Ł; Jacków-Nowicka J; Jacków J
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383666
[TBL] [Abstract][Full Text] [Related]
4. Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomas.
Föll MC; Fahrner M; Gretzmeier C; Thoma K; Biniossek ML; Kiritsi D; Meiss F; Schilling O; Nyström A; Kern JS
Matrix Biol; 2018 Mar; 66():1-21. PubMed ID: 29158163
[TBL] [Abstract][Full Text] [Related]
5. Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa.
Kim M; Murrell DF
Eur J Dermatol; 2015 Apr; 25 Suppl 1():30-2. PubMed ID: 26083672
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous addiction to transforming growth factor-beta signalling in recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma.
Dayal JHS; Mason SM; Salas-Alanis JC; McGrath JA; Taylor RG; Mellerio JE; Blyth K; South AP; Inman GJ
Br J Dermatol; 2021 Apr; 184(4):697-708. PubMed ID: 32726455
[TBL] [Abstract][Full Text] [Related]
7. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.
Cho RJ; Alexandrov LB; den Breems NY; Atanasova VS; Farshchian M; Purdom E; Nguyen TN; Coarfa C; Rajapakshe K; Prisco M; Sahu J; Tassone P; Greenawalt EJ; Collisson EA; Wu W; Yao H; Su X; Guttmann-Gruber C; Hofbauer JP; Hashmi R; Fuentes I; Benz SC; Golovato J; Ehli EA; Davis CM; Davies GE; Covington KR; Murrell DF; Salas-Alanis JC; Palisson F; Bruckner AL; Robinson W; Has C; Bruckner-Tuderman L; Titeux M; Jonkman MF; Rashidghamat E; Lwin SM; Mellerio JE; McGrath JA; Bauer JW; Hovnanian A; Tsai KY; South AP
Sci Transl Med; 2018 Aug; 10(455):. PubMed ID: 30135250
[TBL] [Abstract][Full Text] [Related]
8. TGFβ-signaling in squamous cell carcinoma occurring in recessive dystrophic epidermolysis bullosa.
Knaup J; Gruber C; Krammer B; Ziegler V; Bauer J; Verwanger T
Anal Cell Pathol (Amst); 2011; 34(6):339-53. PubMed ID: 22002724
[TBL] [Abstract][Full Text] [Related]
9. Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa.
Trefzer L; Hess ME; Scholten L; Technau-Hafsi K; Meiss F; Boerries M; Has C; Rafei-Shamsabadi D
Acta Derm Venereol; 2023 Jun; 103():adv4870. PubMed ID: 37338146
[TBL] [Abstract][Full Text] [Related]
10. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Atanasova VS; Pourreyron C; Farshchian M; Lawler M; Brown CA; Watt SA; Wright S; Warkala M; Guttmann-Gruber C; Hofbauer JP; Fuentes I; Prisco M; Rashidghamat E; Has C; Salas-Alanis JC; Palisson F; Hovnanian A; McGrath JA; Mellerio JE; Bauer JW; South AP
Clin Cancer Res; 2019 Jun; 25(11):3384-3391. PubMed ID: 30846478
[TBL] [Abstract][Full Text] [Related]
11. Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
Duong T; Wong D; Barrett A; Price H
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637494
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas.
Illmer J; Zauner R; Piñón Hofbauer J; Wimmer M; Gruner S; Ablinger M; Bischof J; Dorfer S; Hainzl S; Tober V; Bergson S; Sarig O; Samuelov L; Guttmann-Gruber C; Shalom-Feuerstein R; Sprecher E; Koller U; Laimer M; Bauer JW; Wally V
Br J Dermatol; 2023 Dec; 190(1):80-93. PubMed ID: 37681509
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa.
Ng YZ; Pourreyron C; Salas-Alanis JC; Dayal JH; Cepeda-Valdes R; Yan W; Wright S; Chen M; Fine JD; Hogg FJ; McGrath JA; Murrell DF; Leigh IM; Lane EB; South AP
Cancer Res; 2012 Jul; 72(14):3522-34. PubMed ID: 22564523
[TBL] [Abstract][Full Text] [Related]
14. Inherited epidermolysis bullosa dystrophica and squamous cell carcinoma- A case report.
Gayathri E; Anbukkarasi K; Lilly SM
Indian J Pathol Microbiol; 2023; 66(2):360-362. PubMed ID: 37077084
[TBL] [Abstract][Full Text] [Related]
15. Immune Disregulation in Cutaneous Squamous Cell Carcinoma of Patients with Recessive Dystrophic Epidermolysis Bullosa: A Single Pilot Study.
Filoni A; Cicco G; Cazzato G; Bosco A; Lospalluti L; Tucci M; Cimmino A; Foti C; Marzullo A; Bonamonte D
Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207500
[TBL] [Abstract][Full Text] [Related]
16. High levels of type VII collagen expression in recessive dystrophic epidermolysis bullosa cutaneous squamous cell carcinoma keratinocytes increases PI3K and MAPK signalling, cell migration and invasion.
Pourreyron C; Chen M; McGrath JA; Salas-Alanis JC; South AP; Leigh IM
Br J Dermatol; 2014 Jun; 170(6):1256-65. PubMed ID: 24641191
[TBL] [Abstract][Full Text] [Related]
17. Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases.
Montaudié H; Chiaverini C; Sbidian E; Charlesworth A; Lacour JP
Orphanet J Rare Dis; 2016 Aug; 11(1):117. PubMed ID: 27544590
[TBL] [Abstract][Full Text] [Related]
18. Transformation-specific matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas.
Kivisaari AK; Kallajoki M; Mirtti T; McGrath JA; Bauer JW; Weber F; Königová R; Sawamura D; Sato-Matsumura KC; Shimizu H; Csikós M; Sinemus K; Beckert W; Kähäri VM
Br J Dermatol; 2008 Apr; 158(4):778-85. PubMed ID: 18284387
[TBL] [Abstract][Full Text] [Related]
19. Morphological and morphometric analysis of cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa: a retrospective study.
Filoni A; Cicco G; Lospalluti L; Maglietta A; Foti C; Annichiarico G; Resta L; Bonamonte D
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1707-1714. PubMed ID: 31692111
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study.
Robertson SJ; Orrin E; Lakhan MK; O'Sullivan G; Felton J; Robson A; Greenblatt DT; Bernardis C; McGrath JA; Martinez AE; Mellerio JE
Acta Derm Venereol; 2021 Aug; 101(8):adv00523. PubMed ID: 34230977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
